Cargando…

Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets

Non-alcoholic fatty liver disease (NAFLD) is characterized by the excessive and detrimental accumulation of liver fat as a result of high-caloric intake and/or cellular and molecular abnormalities. The prevalence of this pathological event is increasing worldwide, and is intimately associated with o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santos-Laso, Alvaro, Gutiérrez-Larrañaga, María, Alonso-Peña, Marta, Medina, Juan M., Iruzubieta, Paula, Arias-Loste, María Teresa, López-Hoyos, Marcos, Crespo, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773141/ https://www.ncbi.nlm.nih.gov/pubmed/35052726 http://dx.doi.org/10.3390/biomedicines10010046

Ejemplares similares

Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
por: Alonso-Peña, Marta, et al.
Publicado: (2023)

Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease
por: Del Barrio, María, et al.
Publicado: (2023)

Fatty Liver Disease, Metabolism and Alcohol Interplay: A Comprehensive Review
por: Odriozola, Aitor, et al.
Publicado: (2023)

The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease
por: Arias-Loste, María Teresa, et al.
Publicado: (2015)

Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease
por: Arias-Loste, María Teresa, et al.
Publicado: (2016)

Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity
por: Lamadrid, Patricia, et al.
Publicado: (2021)

The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?
por: Iruzubieta, Paula, et al.
Publicado: (2015)

Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNγ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells
por: Arias-Loste, María Teresa, et al.
Publicado: (2021)

Metabolic effects of reduced growth hormone action in fatty liver disease
por: Rufinatscha, Kerstin, et al.
Publicado: (2018)

Irisin, a Link among Fatty Liver Disease, Physical Inactivity and Insulin Resistance
por: Arias-Loste, María Teresa, et al.
Publicado: (2014)

Intraepithelial lymphocytes subsets in different forms of celiac disease
por: Sánchez-Castañon, M., et al.
Publicado: (2016)

LOXL2—A New Target in Antifibrogenic Therapy?
por: Puente, Angela, et al.
Publicado: (2019)

High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort
por: Llop, Elba, et al.
Publicado: (2021)

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2019)

Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy
por: Puente, Angela, et al.
Publicado: (2019)

Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)
por: Lavín-Alconero, Lucía, et al.
Publicado: (2021)

A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression
por: Iruzubieta, Paula, et al.
Publicado: (2020)

Epidemiology of intrafamilial inflammatory bowel disease throughout Europe
por: Arias-Loste, Maria Teresa, et al.
Publicado: (2012)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It
por: Puente, Angela, et al.
Publicado: (2019)

Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding
por: Fortea, José Ignacio, et al.
Publicado: (2018)

Biochemical assessment of metabolic associated fatty liver disease
por: Guerra-Ruiz, Armando R., et al.
Publicado: (2021)

Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease
por: Torres, Jorge-Luis, et al.
Publicado: (2018)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination
por: Crespo, Javier, et al.
Publicado: (2021)

SARS-CoV-2 detection by self-testing: A method to improve surveillance programmes
por: Iruzubieta, Paula, et al.
Publicado: (2021)

SARS-CoV-2 detection by self-testing: A method to improve surveillance programmes
por: Iruzubieta, Paula, et al.
Publicado: (2021)

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
por: Barbier-Torres, Lucía, et al.
Publicado: (2020)

Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy
por: García, María José, et al.
Publicado: (2022)

Metabolic drivers of non-alcoholic fatty liver disease
por: Bence, Kendra K., et al.
Publicado: (2020)

Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home
por: Iruzubieta, Paula, et al.
Publicado: (2021)

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
por: Calleja, José L., et al.
Publicado: (2022)

Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology
por: Akter, Sharmin
Publicado: (2022)

Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease
por: Garbuzenko, Dmitry Victorovich
Publicado: (2022)

Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
por: Grander, Christoph, et al.
Publicado: (2023)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Iravani, Farzaneh, et al.
Publicado: (2018)

Let’s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world
por: Crespo, Javier, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management
por: Jichitu, Alexandra, et al.
Publicado: (2021)

A morphological method for ammonia detection in liver
por: Gutiérrez-de-Juan, Virginia, et al.
Publicado: (2017)

The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
por: Perakakis, Nikolaos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0bcfvp893qdk0ir4oucsfvp7e